Filing Details

Accession Number:
0001104659-13-041514
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-05-14 17:32:13
Reporting Period:
2013-05-14
Filing Date:
2013-05-14
Accepted Time:
2013-05-14 17:32:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1463729 Receptos Inc. RCPT Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1569248 Kristina Burow 8725 West Higgins Road, Suite 290
Chicago IL 60631
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-05-14 129,755 $0.00 129,755 No 4 C Indirect See footnotes
Common Stock Acquisiton 2013-05-14 1,022,283 $0.00 1,136,568 No 4 C Indirect See footnotes
Common Stock Acquisiton 2013-05-14 680,323 $0.00 1,816,891 No 4 C Indirect See footnotes
Common Stock Acquisiton 2013-05-14 284,485 $14.00 2,101,376 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 P Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2013-05-14 973,165 $0.00 129,755 $0.00
Common Stock Series A Preferred Stock Disposition 2013-05-14 7,667,124 $0.00 1,022,283 $0.00
Common Stock Series B Preferred Stock Disposition 2013-05-14 5,102,426 $0.00 680,323 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 13,333 Direct
Footnotes
  1. The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred Stock and Series B preferred Stock, for no additional consideration.
  2. Beneficial ownership consists of an aggregate of 129,755 shares of common stock issued upon conversion of shares of Series A preferred stock held by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"), which may be deemed to beneficially own the shares held by ARCH Fund VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VI. ARCH Partners VI and ARCH VI LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  3. Beneficial ownership consists of: (i) 398,770 shares of common stock held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII") and (ii) 1,702,606 shares of common stock issued upon conversion of shares of Series A preferred stock and Series B preferred stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  4. The managing directors of ARCH VI LLC and ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VI and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Kristina Burow owns an indirect interest in ARCH Partners VI and ARCH Partners VII but does not have voting or investment control over the shares held by ARCH Fund VI or ARCH Fund VII and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.